Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 6Neoplasm Metastasis 3Triple Negative Breast Neoplasms 2Rheumatoid Arthritis, Systemic Juvenile 1Rectal Neoplasms 1Periodic Fevers Syndrome 1Neoplasms 1Mevalonate Kinase Deficiency 1Melanoma 1Lung Neoplasms 1Intestinal Neoplasms 1Cryopyrin-Associated Periodic Syndromes 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Ductal 1Carcinoma 1Bronchiolitis Obliterans Syndrome 1Breast Neoplasms 1Arthritis, Juvenile 1Arthralgia 1Adenocarcinoma of Lung 1Adenocarcinoma 1

Interventions

canakinumab 1Interleukin 1 Receptor Antagonist Protein 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Cryopyrin-Associated Periodic Syndromes × canakinumab × Clear all
NCT02334748 2020-05-19

A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies

Novartis

Phase 3 Completed
31 enrolled 7 charts

Rheumatoid Arthritis, Systemic Juvenile, Bronchiolitis Obliterans Syndrome, Arthritis, Juvenile, Arthralgia, Mevalonate Kinase Deficiency, Cryopyrin-Associated Periodic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡